Slide 1: Growth engine R&D update Biopharma update
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices
Slide 2: Q4 2023 Results - Play to Win
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 2023 Results Play to Win February 1, 2024
Slide 3: Forward-looking statements
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements
Slide 4: Agenda
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Agenda 01 Launch engine to fuel sustainable growth Paul Hudson 02 R&D update Houman Ashrafian 03 Biopharma update Brian Foard, Thomas Triomphe, Olivier Charmeil 04 Consumer Healthcare u
Slide 5: Launch engine to fuel sustainable growth
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Launch engine to fuel sustainable growth
Slide 6: FY 23: Launch performance and Dupixent drive strong growth of Specialty Care and Vaccines
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices FY 2023: Launch performance and Dupixent drive strong growth of Specialty Care and Vaccines Specialty Care Vaccines GenMed • FY 2023 sales of €43.1bn €18.0bn €7.5bn €12.4bn (+5.3%) +14.
Slide 7: Launch engine delivering €731m
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Launch engine delivering 2023 key launches far exceeded originally Total of >€2.2bn sales in 2023 communicated sales expectations of €400m from all Biopharma launches 547 combined (in €
Slide 8: Building an Immunology Powerhouse driven by new launches, Dupixent and Vaccines
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Building an Immunology Powerhouse driven by new launches, Dupixent and Vaccines Pharma launches Low Vaccines GBU ALTUVIIIO, Cablivi, Enjaymo, double-digit Sales of €7.5bn Nexviazyme, Tz
Slide 9: Preparing for the introduction of potential transformative COPD therapies
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Preparing for the introduction of potential transformative COPD therapies with an expected launch of Dupixent later this year Patient population G71 – 2035e U.S. submission EU submissio
Slide 10: Play to win priorities in 2024
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Play to win priorities in 2024 Launch Pipeline Cost Excellence Execution Reallocation Tolebrutinib Reallocation of pipeline RMS/nrSPMS resources (i.e., from oncology to immunology) Rilz
Slide 11: Advancing our commitments to address climate change and leading the SMI Patient Care Pathways working group
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Advancing our commitments to address climate change and leading the SMI Patient Care Pathways working group Reduce Reduce Source Expand GHG emissions GHG emissions renewable eco-car fro
Slide 12: R&D update
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D update
Slide 13: Outstanding pipeline news flow presented at the R&D Day
Growth engine R&D R&D update update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Outstanding pipeline news flow presented at the R&D Day Dupixent lunsekimig amlitelimab RSV toddler vaccine TL1A rilzabrutinib Sarclisa Positive Phase 3 Demonstrated Proof of
Slide 14: Expected major R&D milestones in 2024
Growth engine R&D R&D update update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Expected major R&D milestones in 2024 H1 2024 H2 2024 COPD U.S./EU Approval Dupixent CSU (Study C) Pivotal trial readout RMS (GEMINI 1/2) Pivotal trial readout tolebrutinib n
Slide 15: Unprecedented pipeline of blockbuster opportunities
Growth engine R&D R&D update update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Unprecedented pipeline of blockbuster opportunities Starting multiple Phase 3 and Phase 2 projects in 2024 H1 H2 Ph3 Ph2 Ph3 Ph2 amlitelimab AD amlitelimab HS rilzabrutinib C
Slide 16: Key topics to prepare for the future
Growth engine R&D R&D update update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Key topics to prepare for the future Peak investment Focus Pipeline sustainability Multiple Phase 3 trials Breadth of platforms, Fueled by in-house research launching in para
Slide 17: INBRX-101 acquisition to add innovative asset to rare disease portfolio
Growth engine R&D R&D update update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices INBRX-101 acquisition to add innovative asset with blockbuster potential to rare disease portfolio addressing AAT deficiency • Adding mid-stage asset in Rare Diseases Strateg
Slide 18: Biopharma update
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Biopharma update Q4 2023
Slide 19: Specialty Care performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Specialty Care performance €4.7bn sales +13.7% Q4 2023 Dupixent Dupixent Rare Diseases1 Continued strong demand-driven growth in €2,990m €1,266m approved
Slide 20: Dupixent strong performance in 2023; expected to deliver ~€13bn in 2024
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Dupixent strong performance in 2023; expected to deliver ~€13bn in 2024 Global Dupixent sales (in € m) +34%1 FY performance highlights 10,715 Ex-U.S. U.S.
Slide 21: Top choice for switches driven by efficacy profile
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Top choice for switches driven by efficacy profile Accelerating ALTUVIIIO U.S. launch performance Cumulative patient number with ALTUVIIIO Prescription2 S
Slide 22: Vaccines performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Vaccines performance €2.0bn sales +21.1% Q4 2023 Significant contribution from Beyfortus uptake RSV Polio/ due to “All Infant Protection” recommendation €
Slide 23: Beyfortus lays foundation for best-in-class RSV portfolio
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed Beyfortus lays foundation for best-in-class RSV portfolio Beyfortus launch RSV new development Beyfortus – unprecedented pediatric immunization uptake Inn
Slide 24: GenMed performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed GenMed performance €3.0bn sales -2.4% Q4 2023 Core assets Core assets Industrial sales • Growth of 6.3% in Q4 2023 €1,576m €176m • Continued expansion of
Slide 25: TZIELD - a catalyst for change within Autoimmune T1D
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Specialty Care Vaccines GenMed TZIELD - a catalyst for change within Autoimmune T1D Solid early Screening TZIELD label expansion The 1 Pledge launch in Times Square (U.S.) with Grammy A
Slide 26: Consumer Healthcare update
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Consumer Healthcare update Q4 2023
Slide 27: CHC performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices CHC performance €1.2bn sales +8.5% Q4 2023 Q4 organic growth +4.8% Digestive Wellness Pain Care 11th consecutive growth quarter €322m €275m • Growth supported by price +18.5% +1.0% • Di
Slide 28: Dulcolax: Category leader repeatably performing above market
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Dulcolax: Category leader repeatably performing above market Attractive under- Above penetrated market market growth 3 ~ 1/3 80+ countries Global brand Strong reputation for 3+ WW popul
Slide 29: Financial performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Financial performance Q4 2023
Slide 30: Q4 2023 performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 2023 performance Specialty Care Vaccines GenMed • Q4 sales up 9.3% €4.7bn €2.0bn €3.0bn • Double-digit growth of Specialty +13.7% +21.1% -2.4% Care driven by Dupixent and Rare Diseas
Slide 31: Q4 Group P&L
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 Group P&L €m Q4 2023 Q4 2022 % Change Sales growth Net Sales 10,919 10,725 +9.3% +9.3% Other revenues 1,282 731 +90.8% Gross profit 8,167 7,722 +13.5% Gross margin Gross margin % 74.
Slide 32: FY 2023 Group P&L
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices FY 2023 Group P&L €m FY 2023 FY 2022 % Change Sales growth Net Sales 43,070 42,997 +5.3% +5.3% Other revenues 3,374 2,392 +50.0% Gross profit 32,228 31,697 +7.0% Gross margin Gross marg
Slide 33: Proposed dividend of €3.76
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Proposed dividend of €3.76 1994 2023 Subject to AGM’s approval on April 30, 2024. 33 Investor Relations
Slide 34: Outlook 2024
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Outlook 2024
Slide 35: Strategic cost initiatives, targeting total up to €2bn from 2024 to end of 2025
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Strategic cost initiatives, targeting total up to €2bn from 2024 to end of 2025, to be reallocated in majority Smart Operational Priorities spending excellence In pursuit of first-in-cl
Slide 36: Expected business dynamics in 2024
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Expected business dynamics in 2024 with Q1 marked by high base of comparison FY 2024 Q1 2024 Sales • Dupixent expected to reach approximately €13bn • Vaccines sales expected to grow mid
Slide 37: FY 24 guidance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices FY 2024 guidance EPS growth Currency Low single-digit impact 1 EPS decline approximately (roughly stable at comparable -3.5% to -4.5% tax rate) Barring unforeseen events. 1. Based on Ja
Slide 38: Q&A session
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices Q&A session
Slide 39: R&D appendices
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations R&D appendices
Slide 40: Near-term milestones of our development pipeline
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Near-term milestones of our development pipeline H1 2024 H2 2024 2025 rilzabrutinib ITP Ph3 Dupixent CSU
Slide 41: R&D Pipeline Registration & Phase 3
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations R&D Pipeline Registration & Phase 3 Registration DupixentA Anti-IL-4/IL-13 mAb Chronic Obstructive Pulmon
Slide 42: R&D Pipeline Phase 2
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations R&D Pipeline Phase 2 Immunology & Inflammation Transplant & Type 1 Diabetes DupixentA Anti-IL-4/IL-13 mAb
Slide 43: R&D Pipeline Phase 1
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations R&D Pipeline Phase 1 Immunology & Inflammation Oncology SAR444336 Non-beta IL-2 SynthorinTM molecule Infl
Slide 44: Expected submission timelines
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Expected submission timelines 2024 2025 2026 and beyond tolebrutinib rilzabrutinib Dupixent Nexviazyme Du
Slide 45: Financial appendices
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Financial appendices
Slide 46: GenMed Q4 2023 core assets performance
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations GenMed Q4 2023 core assets performance Core asset sales (in € million) -0.3% +11.4% +13.1% -0.4% 289 272
Slide 47: Q4 main product sales
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Q4 main product sales Q4 2023 sales (€m) Growth Dupixent 2,990 31.3% Influenza vaccines 741 -4.0% Polio/P
Slide 48: FY 2023 main product sales
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations FY 2023 main product sales FY 2023 sales (€m) Growth Dupixent 10,715 34.0% Influenza vaccines 2,669 -5.5%
Slide 49: nirsevimab/Beyfortus Initial agreement Sanofi-AstraZeneca (March 2017)
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations nirsevimab/Beyfortus Initial agreement Sanofi-AstraZeneca (March 2017) Major markets (U.S., FR, DE, ES, I
Slide 50: Sanofi accounting of nirsevimab/Beyfortus updated agreements
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi accounting of nirsevimab/Beyfortus Updated and new agreements Sanofi-AstraZeneca and Sanofi-Sobi (
Slide 51: Q4 sales and EPS currency impact
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Q4 sales and EPS Currency impact Company sales Business EPS +0.31 €1,108m €475m +0.09 €16m -0.01 €-484m -
Slide 52: Net debt evolution in 2023
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Net debt evolution in 20231 € millions 7,793 4,484 896 6,437 4,454 1,236 -9,830 -997 1,113 Net Debt FCF b
Slide 53: Q4 CHC P&L
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Q4 CHC P&L €m Q4 2023 Q4 2022 % Change Sales growth Net Sales 1,215 1,242 +8.5% +8.5% due to Qunol acquis
Slide 54: 2024 currency sensitivity and Q4 2023 currency exposure
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations 2024 currency sensitivity and Q4 2023 currency exposure 2024 Business EPS currency sensitivity Currency e
Slide 55: ESG appendices
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations ESG appendices
Slide 56: Sanofi ESG FY achievements: Affordable access
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi ESG FY achievements Affordable access Ambition Progress FY 2023 FY 2022 Sanofi Reach 1.5 million N
Slide 57: Sanofi ESG FY achievements: R&D for unmet needs
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi ESG FY achievements R&D for unmet needs Ambition Progress FY 2023 FY 2022 Sleeping Develop and sup
Slide 58: Sanofi ESG FY achievements: Planet Care
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi ESG FY achievements Planet Care Ambition Progress FY 2023 FY 2022 Climate change - 55% reduction i
Slide 59: Sanofi ESG FY achievements: In and beyond the workplace
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi ESG FY achievements In and beyond the workplace Ambition Progress FY 2023 FY 2022 Global Gender Am
Slide 60: Sanofi ESG ratings
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Sanofi ESG ratings Rating agencies SCORE Climate 21.2 87/100 79/100 A Change: A B 4.5/5 3.47/5 65/100 Med
Slide 61: Abbreviations
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Abbreviations AA Alopecia Areata GPC3 Glypican-3 PPMS Primary Progressive Multiple Sclerosis AAT Alpha-1-
Slide 62: Collaborations
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices R&D appendices Financial appendices ESG appendices Abbreviations Collaborations Collaborations Ref Name Developed in collaboration with… A Dupixent itepekimab Regeneron Kevzara B frexal
Slide 63: Growth engine R&D update Biopharma update
Growth engine R&D update Biopharma update Consumer Healthcare update Financial performance Outlook 2024 Appendices